Clinical Trials Logo

Clinical Trial Summary

Study design: Allocation: Randomized Endpoint classification: Efficacy study Masking: Open label Primary purpose: Treatment Primary endpoint: Incidence of reaching the target serum trough concentration Secondary endpoint: Clinical efficiency, Antibiotic use, acute kidney injury.


Clinical Trial Description

This is a prospective randomized control trial. There are two groups, study group and control group. Patients of study group accepted vancomycin strategies decided by a serum trough concentration model, and patients of control group accepted vancomycin dosage decided by attending physician. The primary endpoint is the incidence of reaching the target serum trough concentration, the secondary endpoint are clinical efficiency, antibiotic use and side effects such as acute kidney injury, etc. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04088305
Study type Interventional
Source Peking University Third Hospital
Contact
Status Completed
Phase Phase 4
Start date October 1, 2019
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Terminated NCT02940626 - Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus. Phase 2
Completed NCT01925066 - Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation Phase 2